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1. Introduction 
Prosthesis-patient mismatch (PPM) was first described over 30 years ago (Rahimtoola, 1978) 
for aortic valve replacement: when the in vivo effective orifice area (EOA) of the prosthetic 
valve is less than that of the native, non-diseased, human valve. Extensive documentation 
on the role of PPM after aortic valve replacement (AVR) particularly addresses left 
ventricular mass regression and patient survival. Controversy continues about the influence 
of PPM on patient survival, both early and late mortality. Many studies (Pibarot and 
Dumesnil, 2000; Muneretto et al., 2004; Mohty et al., 2006; Tasca et al., 2006; Moon et al., 
2006; Florath et al., 2008; Mohty et al., 2009; Blais et al., 2003) report PPM to be an 
independent predictor of mortality while others (Jamieson et al., 2010; Kato et al., 2007; 
Vicchio et al., 2008; Mascherbauer et al., 2008; Monin et al., 2007)  showed no significant 
effect of PPM on patient outcome. There is also debate about whether the control of PPM 
reduces congestive heart failure and regression of the left ventricular mass, thereby 
contributing to improved survival. Several Canadian centers have been actively involved in 
this area of research, namely the Laval University group led by P. Pibarot, J.G. Dumesnil 
and D. Mohty, the UBC group led by W.R.E. Jamieson, and the University of Ottawa group 
led by M. Ruel and A. Kulik.  
PPM is categorized by Pibarot and Dumesnil (2000), Mohty et al. (2009), and Jamieson et al. 
(2010) as normal (EOA index (EOAI) of > 0.85 cm2 / m2), mild-to-moderate (> 0.65 cm2 / m2 
to ≤ 0.85 cm2 / m2), and severe (≤ 0.65 cm2 / m2). Tasca et al. (2006) defined PPM as an EOAI 
of ≤ 0.80 cm2 / m2, Moon et al. (2006) as an EOAI of < 0.75 cm2 / m2, while Ruel et al. (2004), 
Kulik et al. (2006), Kato et al. (2007), and Monin et al. (2007) as EOAI of ≤ 0.85 cm2 / m2; 
Florath et al. (2008) and Vicchio et al. (2008) chose 0.60 cm2 / m2 as the cutoff between 
moderate and severe PPM. As can be seen, there is no clear consensus on the exact definition 
of PPM; this lack of consensus may contribute at least in part to the observed discrepancies 
in the conclusions of the studies. The studies also differ in the length of their patient follow-
up. Jamieson et al. (2010) report survival to 15 years, Moon et al. (2006) and Mohty et al. 
(2009) to 12 years, and the majority of the other publications on the topic of PPM report 
survival from 4 to 8 years (Mothy et al. 2006; Tasca et al., 2006; Florath et al., 2008; Kato et 
al., 2007; Mascherbauer et al., 2008; Monin et al., 2007). These differences may also 
contribute to the different conclusions reached.  
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It should be noted that the indication for surgical management of aortic stenosis is 
symptomatic severe aortic stenosis (< 1.0 cm2 valve area). In the majority of patients, this is 
equivalent to an EOAI at or below the level of severe mismatch by our definition. 
2. The influence of PPM on postoperative patient outcomes 
The objective of our study (Jamieson et al., 2010) on 3,343 patients having AVR for severe 
aortic stenosis or mixed aortic stenosis/insufficiency was to determine the predictors for all 
levels of PPM on mortality and to determine if there is a relationship between PPM and 
other predictors of survival. The prostheses used were contemporary stented bioprostheses 
(2493) and mechanical prostheses (850). More specifically, 667 patients had Carpentier-
Edwards PERIMOUNT pericardial prostheses (Edwards Lifesciences, Irvine, CA), 1250 
patients had Carpentier-Edwards supra-annular porcine prostheses, 576 patients had 
Medtronic Mosaic porcine prostheses (Medtronic, Minneapolis, MN), 462 patients had St. 
Jude Medical mechanical prostheses (St. Jude Medical, St. Paul, MN), and 388 patients had 
CarboMedics mechanical prostheses (Sorin-CarboMedics, Saluggia, Italy) (Figure 1). There is 
a misconception with the Carpentier-Edwards supra-annular aortic valve for the early 
version (prior to 1985) of the mitral valve failed because of stent-post dehiscence due to 
excessive trimming of the aortic wall; however, this failure mode was identified in only one 
aortic prosthesis before the manufacturing trimming was changed (Jamieson et al., 2005; 
Jamieson et al, 2009). The level of PPM was classified for each patient based on reference 
EOAs and size for each prosthesis in the published literature. The patients considered for 
the study had their first aortic valve replacement. Patients who had a subsequent valvular 
replacement were censored alive on the date of the reoperative procedures. This concept 
was to avoid a hemodynamically different prosthesis at the time of reoperative explantation. 
  
Carpentier-Edwards         Carpentier-Edwards        Medtronic Mosaic
SAV                                Perimount
       St. Jude Medical
(Standard, HP & Regent)
(Standard, R Series, Top Hat)
CarboMedics
 
Fig. 1. Contemporary prostheses used in Jamieson et al. (2010) 
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The results of Jamieson et al. (2010) (N = 3343) are compared with those of Molty et al. (2009) 
(N = 2576); J.G. Dumesnil and P. Pibarot, two of the more prominent investigators in the 
area of PPM, were also authors of the 2009 study.  
 
 Jamieson et al. 2010 (Overall) UBC Study Mohty et al. 2009 (Late) Laval Study 
 NS 
PPM 
(N = 3343) 
Moderate 
PPM 
(N = 1547) 
Severe PPM
(N = 212) 
NS PPM 
(N = 1739) 
Moderate 
PPM 
(N = 797) 
Severe PPM 
(N = 40) 
Pre-operative data 
Age, yrs 66 ± 11 69 ± 10 69 ± 12 68 ± 10 71 ± 9 69 ± 11 
Female, % 29 36 57 33 50 67 
BSA, m2 1.8 ± 0.2 1.9 ± 0.2 2.0 ± 0.3 1.8 ± 0.2 1.8 ± 0.2 1.9 ± 0.3 
BMI, kg/m2 26 ± 4 28 ± 5 32 ± 8 26 ± 5 29 ± 5 32 ± 7 
Hypertension 19 27 28 54 59 68 
NYHA class 
III/IV 
77 75 68 61 68 67 
LVEF < 50%, % 19 19 18 19 17 18 
Operative data 
Mechanical 
prosthesis, % 
32 19 23 24 14 43 
Prosthesis size 
≤21mm, % 14 42 91 16 38 80 
Concomitant 
CABG 
40 47 44 43 46 58 
EOAI, cm2 / m2 0.99 ± 0.15 0.76 ± 0.05 0.60 ± 0.04 1.10 ± 0.20 0.80 ± 0.05 ± 0.04 
NS = nonsignificant; PPM = prosthesis-patient mismatch (see text for description of the categories);  
BSA = body surface area; BMI = body mass index; NYHA = New York Heart Association; LVEF = left 
ventricular ejection fraction; CABG = coronary artery bypass grafting 
Table 1. Descriptive preoperative and operative data of the two patient cohort studies: 
Overall (2010) and Late (2009) 
As can be seen, the preoperative and operative characteristics of both cohorts are quite 
comparable, with the exception of hypertension and female gender, both of which higher in 
the Mohty et al. cohort. Also, 46.3% of patients were classified as having no PPM, 47.4% as 
mild-to-moderate PPM, and 6.3% as severe PPM in the Jamieson et al. cohort, whereas 67.5% 
of the patients had no PPM, 30.9% had moderate PPM, and 1.6% had severe PPM in the 
Mohty et al. cohort. The Jamieson et al. data analysis was based primarily on overall 
survival (early + late), whereas Mohty et al. took only late mortality into account because 
early mortality in the same cohort had already been analyzed by Blais et al. (2003). 
Jamieson et al. found no significant difference in early mortality between the EOAI 
categories (no PPM: 3.4%, mild-to-moderate PPM: 3.5%, and severe PPM: 2.8%), or in late 
mortality (no PPM: 33.0%, moderate PPM: 30.2%, and severe PPM: 29.2%). The freedom 
from cardiac death by EOAI categories was also not significant (no PPM: 68.7 ± 2.4%, 
moderate PPM: 68.9 ± 2.6%, and severe PPM: 58.9 ± 9.7%, p = 0.699). In addition, the 
freedom from valve-related mortality was not significantly different by EOAI categories (no 
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PPM: 84.3 ± 2.0%, moderate PPM: 85.7% ± 1.9%, and severe PPM: 76.8 ± 9.6%, p = 0.998). The 
overall (early + late) survival, at 15 years, was 38.1 ± 2.1%  for no PPM, 37.0 ± 2.2% for mild-
moderate PPM, and 22.1 ± 6.5% for severe PPM (no PPM versus severe PPM: p=0.040) 
(Figure 2).  
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Fig. 2. Freedom from late and overall mortality by three effective orifice area index (EOAI) 
groups (N = 3343) (Jamieson et al., 2010). E1 (solid line), not significant; E2 (long-dash line), 
mild to moderate; and E3 (short-dash line), severe. (AVR = aortic valve replacement; BP = 
bioprosthesis; MP = mechanical prosthesis) 
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However, Mohty et al. found survival to be significantly lower for patients with severe PPM 
(5-year survival: no PPM: 84 ± 1%, moderate PPM: 81 ± 2%, severe PPM: 74 ± 8%; 10-year 
survival: no PPM: 61 ± 2%, moderate PPM: 57 ± 3%, severe PPM: 40 ± 10%). Freedom from 
cardiovascular-related death was also found to be significantly lower in patients with severe 
PPM (5-year survival: no PPM: 93 ± 1%, moderate PPM: 90 ± 1%, severe PPM: 78 ± 7%; 10-
year survival: no PPM: 81 ± 2%, moderate PPM: 77 ± 3%, severe PPM: 50 ± 11%). 
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100
  80
  60
  40
  20
    0
Late (Overall) Survival
A
Freedom From Cardiovascular
                   Death (%)
B
P = 0.008 P < 0.0001
 
Fig. 3. Late overall survival and freedom from cardiovascular death (from Mohty et al., 
2009). Brown line indicates nonsignificant prosthesis-patient mismatch (PPM); green line 
indicates moderate PPM; orange line shows severe PPM 
The conclusion by Mohty et al. that severe PPM is an independent predictor of late mortality 
in patients undergoing AVR differs from the conclusion by Jamieson et al. that PPM is not a 
predictor of survival. It should be noted that the severe PPM group consisted of 40 patients 
(1.6%) in the Mohty cohort whereas it consisted of 212 patients (6.3%) in the Jamieson 
cohort. The very small percentage of patients with severe PPM in the Mohty et al. study 
could be attributed to the fact that [1] only patients who survived through the short-term 
period following AVR were included (whereas all patients undergoing AVR was included 
in the Jamieson et al. study), and [2] the short-term mortality was much higher in the Mohty 
cohort (7 out of 27 patients with severe PPM, 25.9%), compared with the Jamieson cohort (6 
out of 212, 2.8%), and therefore not as many patients in the severe PPM survived past the 
early period to be included in the Mohty et al. study. The finding of severe PPM as a 
significant predictor of survival may be purely related to the small group size. In other 
words, if the group had consisted of more patients, severe PPM may not have been found to 
be an independent predictor. The discrepancy between the findings of these two studies 
warrants further investigation.  
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In Jamieson et al., age, NYHA class III/IV, concomitant CABG, renal failure and dialysis, 
and emergent preoperative status were found to be predictors of early mortality (114/3343, 
3.4%) on multivariate analysis. Because a univariate analysis of the various EOAI categories 
showed no significance in early mortality, there was no need for a multivariate analysis on 
PPM versus early mortality. A study by Blais et al. (2003) revealed LVEF < 40%, infectious 
endocarditis, emergent status, cardiopulmonary bypass time, chronic lung disease, and 
moderate-severe PPM to be independent predictors of early mortality (58/1266, 4.6%). 
Again, the short-term mortality in the severe PPM category was much higher in Blais et al. 
(7 out of 27 patients with severe PPM, 25.9%) than in Jamieson et al. (6 out of 212 patients, 
2.8%), which may have contributed to the significant finding by Blais et al. that severe PPM 
was an independent predictor of survival (Figure 4). It is not clear why early mortality was 
so high in Blais et al. 
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Fig. 4. Relative risk ratio for short-term mortality according to the presence and severity of 
valve prosthesis-patient mismatch (from Blais et al., 2003). Numbers above the bars indicate 
the relative risk ratio for mortality compared with the group with nonsignificant mismatch 
The predictors for late mortality, identified in a multivariate analysis in Jamieson et al. were 
age, male gender, NYHA functional class III/IV, concomitant coronary artery bypass, LVEF 
< 35%, BMI < 18, BMI > 35, bioprosthesis, preoperative congestive heart failure, diabetes 
mellitus, renal failure, and chronic obstructive pulmonary disease. In comparison, Mohty et 
al. (2009) found age, coronary artery disease, diabetes, renal failure, chronic lung disease, 
mechanical prosthesis, and severe PPM to be multivariate predictors of late mortality.  
Jamieson et al. found EOAI to have no predictive effect on survival, whether early, late, or 
overall, despite the survival curves differing by EOAI categories (38.1 ± 2.1% 15-year overall 
survival for no PPM, 37.0 ± 2.2% for mild-to-moderate PPM, and 22.1 ± 6.5% for severe 
PPM). The reasons for the differences in survival curves are related to the complexity of the 
patients in the three categories, especially the category of severe PPM for ≤ 60 years and 
ejection fraction ≤ 50%, rather than a direct contribution from PPM.  
Survival was adjusted in Jamieson et al. to determine the effect of covariates (EOAI, age, 
BMI, and EF). Severe EOAI had no relationship on adjusted survival for the evaluated 
covariates, except for very low level of significance for EF > 50%.  
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The influence of BMI was further evaluated (Yamashita et al., personal communication). 
Overweight or mild-to-moderately obese patients had a lower risk of early mortality, while 
underweight and severely obese patients had a higher risk of late mortality. When patients 
were analyzed as normal/underweight or overweight/obese, those with a normal EOAI 
had better 15-year survival than those with severe PPM. After adjusting for EOAI, age > 60 
years and EF ≤ 50% indicated a higher risk of overall (early + late) mortality within BMI 
categories. These results suggest that BMI is associated with survival after AVR and that 
PPM may modify the effect. 
EOAI was also evaluated as a continuous variable (along with other variables except EF), 
as well as a categorical variable, which revealed that EOAI was not an independent risk 
factor for late (> 30 days) or overall mortality. The predictors, otherwise, were not 
different from the categorical modeling except for the elimination of valve size and the 
addition of BMI for early mortality. Valve type was eliminated for late mortality and 
overall mortality. 
The survival curves in Jamieson et al. show that severe PPM (EOAI of ≤ 0.65 cm2/m2) 
reduces survival for patients > 60 years old but not for patients ≤ 60 years old, that severe 
PPM reduces survival for patients with a BMI ≥ 25kg/m2 but not for those with a BMI < 25 
kg/m2, and that severe PPM reduces survival for patients with an ejection fraction > 50% 
but not for those with an EF ≤ 50% (Figure 5). In comparison, Mohty et al. found that severe 
PPM was associated with increased mortality in patients < 70 years old but not in older 
patients, and that it significantly affected survival in patients with a BMI < 30kg/m2 but not 
in those with a BMI ≥ 30kg/m2 (Figure 6A, 6B, 6C, 6D). They also found moderate-to-severe 
PPM to be an independent predictor of late mortality in patients with a pre-operative LVEF 
< 50% but not in those with preserved LV systolic function (Figure 6E, 6F). With regard to 
these discrepancies, it is worth noting that there were only 21 patients in the Jamieson et al. 
BMI < 25 kg/m2 severe PPM group and 39 patients in the LVEF ≤ 50% severe PPM group, 
while for the severe PPM subset of the Mohty cohort, there were fewer than 20 patients in 
each of the < 70 years old, ≥ 70 years old, BMI < 30 kg/m2, and BMI ≥ 30kg/m2 subgroups. 
We therefore believe that the discrepancies in the above results may be purely due to 
random variations in the small data sets, and that if given an adequate number of cases in 
each of the categories, there may be no differences in the results between the Jamieson et al. 
and the Mohty et al. groups. 
Ruel et al. (2006) found that PPM primarily affected patients with impaired left ventricular 
function at the time of AVR, and patients in whom PPM was associated with decreased 
overall long-term survival, lower freedom from heart failure, and diminished left 
ventricular mass regression. Also, an EOAI ≤ 0.85 cm2 / m2 did not have a significantly 
detrimental effect in patients with normal preoperative left ventricular function. However, 
the authors pointed out that PPM might have been found to have a significant effect in the 
normal LV function cohort had they evaluated cases with severe mismatch (≤ 0.65 cm2 / m2). 
An earlier study by Ruel et al. (2004) had shown that although PPM  had significant effects 
on cardiac end points (occurrence of congestive heart failure, etc), it had no effect on overall 
survival after AVR. Kulik et al. (2006) found that patients with low-gradient aortic stenosis 
(LGAS, defined as an aortic valve area of < 1.2cm2, a mean transvalvular pressure gradient 
of < 40 mmHg, and a LVEF of < 50%) have worse long-term outcomes after AVR, and that 
PPM further adversely affects the long-term outcomes of LGAS patients and should 
therefore be avoided in this population.  
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Fig. 5. Freedom from overall mortality in various subdivisions of the three effective orifice 
area index (EOAI) groups (Jamieson et al., 2010, and Jamieson, Personal Communication). 
E1 (solid line), not significant; E2 (long-dash line), mild to moderate; and E3 (short-dash 
line), severe. (EF = ejection fraction; BMI = body mass index) 
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Fig. 6. Impact of prosthesis-patient mismatch on late overall survival (from Mohty et al. 
2009, Figure 2). (A) Patients < 70 years old, (B) Patients ≥ 70 years old, (C) Body mass 
index (BMI) < 30 kg/m2, (D) BMI ≥ 30 kg/m2, (E) Pre-operative left ventricular ejection 
fraction (LVEF) < 50%, (F) LVEF ≥ 50%. Brown line indicates nonsignificant prosthesis-
patient mismatch (PPM); green line indicates moderate PPM; orange line shows severe 
PPM 
In the Jamieson et al. cohort of 3343 patients, an additional study (Higgins et al., 2011) that 
evaluated the influence of gender on early, late, and overall survival reported that the 
predictors of mortality after AVR for aortic stenosis differed between male and female 
patients. Female gender was a predictor of early mortality while male gender was a 
predictor of late (but not early or overall) mortality. Male gender increased the risk of late 
mortality, and a valve size ≤ 21 mm increased the risk of early and overall mortality among 
male patients only. These differences need to be taken into consideration preoperatively and 
require consideration during operative management. 
The Jamieson et al. analysis indicated that severe PPM identified with an EOAI < 0.65 cm2/m2 
is not an independent predictor of early mortality, late mortality, or overall mortality after 
AVR. These findings have been discussed in perspective with other studies that have and 
have not provided evidence of PPM as an independent predictor of survival. The 
independent influence of bioprostheses as a risk factor of late and overall mortality also 
needs extensive evaluation because currently bioprostheses are recommended for patients ≥ 
60 years old to minimize serious valve-related morbidity and provide a relatively acceptable 
degree of valve-related reoperation for structural valve deterioration. Valve-related 
mortality is not influenced by valve type (bioprosthesis or mechanical prosthesis). The  
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documented finding that AVR does not provide the same age/gender matched survival as 
in the general population allows this lower age threshold for bioprostheses in AVR (van 
Geldrop et al., 2009). This earlier failure threshold may be related to residual systolic 
dysfunction and more likely related to diastolic dysfunction concomitant with PPM 
(Nozohoor et al., 2008). 
3. A suggested approach to PPM 
Because the negative impact of severe PPM on postoperative survival, it is crucial to avoid 
leaving patients with severe PPM after valvular surgery. Pibarot and Dumesnil (2000) 
presented a 3-step approach for preventing PPM: [1] calculate the patient’s body surface 
area from weight and height; [2] using a BSA versus EOAI table, find the minimal valve 
EOA (in cm2) that will allow a given patient to have proper (ideally > 0.85 cm2 / m2) EOAI 
after surgery; and [3] select the type and size of prosthesis that has EOA reference values 
equal to or greater than the minimal valve EOA value obtained in step 2. The occurrence 
and severity of postoperative PPM can also be predicted before the operation from the 
patient’s BSA and the reference EOA value of the selected prosthesis (Pibarot et al., 2001; 
Urso et al., 2010; Dumesnil and Pibarot, 2010).  
In agreement with the above, despite failing to find severe PPM (< 0.65 cm2 / m2) as an 
independent predictor of early, late, or overall mortality after AVR, we recommend that 
surgeons do not leave patients with a severe mismatch (especially for bioprostheses, which 
may develop degenerative changes over time that would further reduce the EOAI). 
Surgeons should maintain a prospective strategy of implanting an adequately sized aortic 
prosthesis that will preclude patients from being in the category of severe mismatch (near 
equivalent to indications for intervention in severe aortic stenosis). However, a significant 
portion of patients undergoing AVR will have some level of mild-to-moderate PPM owing 
to the intrinsic obstructive nature of most prostheses, and Jamieson et al. (2010) should 
provide some confidence to surgeons and cardiologists that mild-to-moderate PPM is 
unlikely to be detrimental to survival. 
 Other than selecting a prosthesis with sufficient EOA, as described above, there are several 
more intraoperative options available to surgeons to prevent the occurrence of severe PPM. 
Aortic root enlargement may be considered in patients with an elevated risk of developing 
moderate-to-severe PPM at time of valvular replacement surgery (Mohty et al., 2006). Kulik 
et al. (2008) were able to insert larger prosthetic valves and achieve lower PPM by doing 
aortic root enlargement (ARE) at the time of AVR. They reported that the addition of an 
ARE to AVR increased the aortic cross-clamp time by 9.9 minutes, on average, and that there 
was no significant increase in perioperative morbidity or mortality associated with the 
added ARE. However, the lower incidence of PPM did not significantly affect long-term 
outcomes in their AVR + ARE cohort, once again coming back to the question of whether 
PPM significantly affects survival. The third option is a total aortic root replacement. 
Compared with a traditional stented bioprosthesis, total root replacement allows for optimal 
hemodynamics with no significant aortic regurgitation, improved regression of the LV mass, 
and less PPM in the small aortic root (Kon et al., 2002; Kincaid et al., 2007); however, total 
aortic root replacement comes at the cost of increased operative mortality, and a longer 
learning process. Several biological valves that allow for this procedure are the Medtronic 
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Freestyle (porcine, stentless), Edwards Prima Plus (porcine, stentless), and Sorin Pericarbon 
Freedom (pericardial, stentless) (Jamieson, 2010). Finally, a myectomy and a  myotomy of 
the hypertrophied muscle are options for dealing with a small aortic root or a left 
ventricular outflow tract obstruction; they are safe and effective procedures without 
additional complications when done concomitantly with AVR (Kayalar et al., 2010). 
Myectomy-myotomy also has improved left ventricular mass regression after AVR for pure 
aortic stenosis (Tasca et al., 2003). 
Among the three available intraoperative options available to surgeons to prevent the 
occurrence of severe PPM, the first option to consider for any patient should be to look for 
a valve with larger a EOAI and better hemodynamics. The On-X valve and the St. Jude 
Medical (SJM) Regent valve are mechanical valves with improved hemodynamics. The On-
X valve by On-X Life Technologies Inc. also has improved hemodynamics (Palatianos et al., 
2007; Chambers et al., 2005) and excellent postoperative EOA and transvalvular gradients 
(Moidl et al., 2002). The On-X valve was also designed to address the problems of 
occasional incidents of unexplained hemolytic anemia, tissue interference, excessive 
pannus overgrowth, and thrombotic complications (Moidl et al., 2002). The SJM Regent 
valve is an improvement on the SJM conventional valve, and has a wider valve area than 
the SJM HP valve (Sezai et al., 2010). With its supra-annular placement, several studies 
have suggested that using the Regent valve practically circumvents the need for root 
enlargement (Bach et al., 2002; Petracek, 2002). In a recent study (Okamura et al., 2010) in 
which 50 patients were given a small-sized (17-mm or 19-mm) St. Jude Regent mechanical 
valve, all patients improved to NYHA functional class II or better. Several biological valves 
with improved hemodynamics are the Carpentier-Edwards PERIMOUNT Magna Ease 
(pericardial), SJM Epic Supra (porcine), Sorin Soprano Armania (pericardial), and 
Medtronic Mosaic Ultra (porcine) valves (Jamieson, 2010). The Sorin Mitroflow 
(pericardial) and the St Jude Medical Trifecta (pericardial) (approved 2007 and 2010, 
respectively by the USFDA) are externally mounted pericardial bioprostheses and not 
amenable to increased diameter design. 
For patients who have already developed moderate or severe postoperative PPM, 
reoperation may be an option to improve long-term survival (Girard et al., 2001). In Girard 
et al., there were no 30-day deaths for reoperations on 12 patients with isolated, severe PPM. 
However, 5 of the 9 patients who underwent concomitant major cardiac procedures at the 
time of valvular replacement died in-hospital, so there is a risk to reoperation. The benefit of 
relief from PPM must be weighed carefully against the risks of reoperation, and must be 
assessed on a patient-by-patient basis. When evaluating patients with mild-to-moderate 
PPM for the possibility of reoperation, we suggest that surgeons take into account the 
Jamieson et al. (2010) finding of the unlikelihood of mild-to-moderate PPM contributing to 
worse survival. 
From the accumulated data from published literature, it is easy to see that the topic of 
prosthesis-patient mismatch remains controversial. The issue is further complicated by the 
fact that there are several levels of PPM (nonsignificant, mild, moderate, or severe), with 
different studies showing different outcomes for each level of PPM. There is also currently 
no clear consensus on the exact definitions of PPM and its categories. 
A sensible approach to the issue of PPM is that we should avoid generalizations for any 
given level of PPM except for severe PPM, for which the data in the existing literature is 
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more consistent; therefore, proactive measures should be taken to prevent its occurrence. 
For other levels of PPM, it is reasonable to evaluate each patient on an individual basis (i.e., 
moderate PPM being more acceptable for a sedentary elderly patient, but less so for 
someone who is younger and more active), and for surgical and postoperative management 
options to be dependent on the individualized assessment.  
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